Deal via Aegis Capital includes $1.28 million greenshoe
By Marisa Wong
Madison, Wis., June 23 – Signal Genetics Inc. said it closed its $8.5 million initial public offering of stock with a $1.28 million greenshoe. The deal was announced June 2 and priced on June 17.
The company will sell 850,000 common shares at $10.00 per share with a greenshoe for up to 127,500 of additional shares.
Aegis Capital Corp. is the bookrunning manager.
As previously announced, proceeds will be used to fund continued clinical development of AMG indication for the company’s MyPRS test and for expansion of its commercial organization, the establishment of its San Diego corporate headquarters, the hiring of an executive team to manage and grow the business, including a chief financial officer with public company experience and a chief commercial officer, the repayment of funds advanced by LeBow to pay offering expenses, working capital and general corporate purposes.
Signal Genetics is an emerging commercial stage, molecular diagnostic company based in New York focused on providing innovative diagnostic services. The company’s shares will trade on the Nasdaq under the symbol “SGNL.”
| Issuer: | Signal Genetics Inc.
|
| Issue: | Common stock
|
| Amount: | $8.5 million
|
| Greenshoe: | $1,275,000
|
| Shares: | 850,000
|
| Price: | $10.00
|
| Warrants: | No
|
| Bookrunner: | Aegis Capital Corp.
|
| Announcement date: | June 2
|
| Pricing date: | June 17
|
| Settlement date: | June 23
|
| Stock exchange: | Nasdaq: SGNL
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
